Table 1 Individual case characteristics included in this SR

Joshi et al. [17]

India

19

F

NR

0

Yalçinkaya et al. [18]

Turkey

12

M

mRNA vaccine (Pfizer-BioNTech)

1

DeJong et al. [19]

USA

14

F

Pfizer vaccine

1

Abdelgalil et al. [20]

Saudi Arabia

12

M

Moderna vaccine

1

McGann et al. [21]

New Zealand

16

M

Pfizer-BioNTech mRNA SARS-CoV-2

1

Miyazato et al. [22]

Japan

32

M

BNT162b2(Pfizer-BioNTech

1

Choi et al. [23]

South Korea

22

F

ChAdOx1 COVID-19 vaccine (AstraZeneca

1

Bova et al. [24]

Italy

46

M

Ad26. COV2. S vaccine (Johnson &Johnson/Janssen)

1

Chai et al. [25]

Denmark

17

M

Pfizer-BioNTech

1

Poussaint et al. [26]

USA

12

M

Pfizer-BioNTech

1

Lee et al. [27]

United States

13

M

Pfizer/BioNTech vaccine (BNT162b2)

1

Al Bishawi et al. [28]

Qatar

37

F

Modern mRNA vaccine

1

Park et al. [29]

Korea

67

M

AstraZeneca vaccine / ChAdOx1 nCoV-19

1

Buchhorn et al. [30]

Germany

18

M

Pfizer/BionTech (BNT162b2)

1

Grome et al. [41]

USA

in 30 s

M

Pfizer/BioNTech mRNA COVID-19 vaccine

0

Nune et al. [15]

UK

44

F

Pfizer-BioNTech mRNA vaccine

1

Uwaydah et al. [31]

United Arab Emirates

22

M

inactivated SARS-CoV-2 vaccine

1

Agarwal et al. [32]

India

28

M

NR

1

Bangash et al. [33]

USA

21

F

J&J COVID-19 vaccine

1

Deb et al. [34]

USA

67

M

Moderna COVID-19 vaccine

1

Koga et al. [36]

Japan

15

M

m RNA (Moderna)

1

Lieu et al. [37]

Canada

21

F

m RNA (Moderna)

NR

Baicus et al. [38]

Romania

22

M

BNT162b2

1

Kahn et al. [39]

USA

20

M

(Pfizer-BioNTech)

1

Taneja et al. [40]

India

27

M

1

Salzman et al. [35]

USA

20

F

Pfizer-BioNTech

1

40

M

1

18

M

1

Ouldali et al. [42]

France

12–17

M

BNT162b2 vaccine (mRNA vaccine)

1

M

1

M

1

M

1

M

1

M

1

F

1

M

1

M

1